Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 1/2019

01-01-2019 | Original Article

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer

Authors: Aliyah M. Weinstein, Nicolas A. Giraldo, Florent Petitprez, Catherine Julie, Laetitia Lacroix, Frédérique Peschaud, Jean-François Emile, Laetitia Marisa, Wolf H. Fridman, Walter J. Storkus, Catherine Sautès-Fridman

Published in: Cancer Immunology, Immunotherapy | Issue 1/2019

Login to get access

Abstract

IL-1 family cytokines play a dual role in the gut, with different family members contributing either protective or pathogenic effects. IL-36γ is an IL-1 family cytokine involved in polarizing type-1 immune responses. However, its function in the gut, including in colorectal cancer pathogenesis, is not well appreciated. In a murine model of colon carcinoma, IL-36γ controls tertiary lymphoid structure formation and promotes a type-1 immune response concurrently with a decrease in expression of immune checkpoint molecules in the tumor microenvironment. Here, we demonstrate that IL-36γ plays a similar role in driving a pro-inflammatory phenotype in human colorectal cancer. We analyzed a cohort of 33 primary colorectal carcinoma tumors using imaging, flow cytometry, and transcriptomics to determine the pattern and role of IL-36γ expression in this disease. In the colorectal tumor microenvironment, we observed IL-36γ to be predominantly expressed by M1 macrophages and cells of the vasculature, including smooth muscle cells and high endothelial venules. This pattern of IL-36γ expression is associated with a CD4+ central memory T cell infiltrate and an increased density of B cells in tertiary lymphoid structures, as well as with markers of fibrosis. Conversely, expression of the antagonist to IL-36 signaling, IL-1F5, was associated with intratumoral expression of checkpoint molecules, including PD-1, PD-L1, and CTLA4, which can suppress the immune response. These data support a role for IL-36γ in the physiologic immune response to colorectal cancer by sustaining inflammation within the tumor microenvironment.
Appendix
Available only for authorised users
Literature
3.
go back to reference Ribassin-Majed L, Le Teuff G, Hill C (2017) La fréquence des cancers en 2016 et leur évolution. Bull Cancer 104:20–29CrossRefPubMed Ribassin-Majed L, Le Teuff G, Hill C (2017) La fréquence des cancers en 2016 et leur évolution. Bull Cancer 104:20–29CrossRefPubMed
12.
go back to reference Penha R, Higgins J, Mutamba S et al (2016) IL-36 receptor is expressed by human blood and intestinal T lymphocytes and is dose-dependently activated via IL-36β and induces CD4+ lymphocyte proliferation. Cytokine 85:18–25CrossRefPubMed Penha R, Higgins J, Mutamba S et al (2016) IL-36 receptor is expressed by human blood and intestinal T lymphocytes and is dose-dependently activated via IL-36β and induces CD4+ lymphocyte proliferation. Cytokine 85:18–25CrossRefPubMed
41.
45.
go back to reference Wang Z-S, Cong Z-J, Luo Y et al (2014) Decreased expression of interleukin-36α predicts poor prognosis in colorectal cancer patients. Int J Clin Exp Pathol 7:8077–8081PubMedPubMedCentral Wang Z-S, Cong Z-J, Luo Y et al (2014) Decreased expression of interleukin-36α predicts poor prognosis in colorectal cancer patients. Int J Clin Exp Pathol 7:8077–8081PubMedPubMedCentral
Metadata
Title
Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer
Authors
Aliyah M. Weinstein
Nicolas A. Giraldo
Florent Petitprez
Catherine Julie
Laetitia Lacroix
Frédérique Peschaud
Jean-François Emile
Laetitia Marisa
Wolf H. Fridman
Walter J. Storkus
Catherine Sautès-Fridman
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 1/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-018-2259-0

Other articles of this Issue 1/2019

Cancer Immunology, Immunotherapy 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine